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Introduction: Healthcare Spending Costs
• Overall out-of-pocket costs have risen to $61 billion in 2018
Aitken M, Kleinrock M. Medicine Use and Spending in the U.S. IQVIA Insitute for Human Data Science; 2019. Accessed November 3, 2019.
Healthcare spending impact on patients? 
Spending on prescription 
medications is expected to rise 
to $420 billion by 2023.2
Nearly 30% of patients reported 
not taking prescription due to 
cost. 






trials are valuable to 
understand efficacy, active 
comparator trial designs 
provide data that can guide 
clinical decision making by 
allowing direct comparisons 
between similar drugs 
Active Comparators in Dermatology Topical Trials
In dermatology, subtle 
changes in concentration 
or combination of topical 
agents can be classified 
as a novel product. 
0.3%0.1%
While some new medications 
may improve patient 
outcomes, others may not 
offer meaningful benefit over 
existing less costly 
alternatives.  
The  Inquiry Question: 
To evaluate trends in the use of active comparator trial 
designs for topical medications approved by the FDA 
between January 2002 and December 2020. 
Methods
• Population




• Clinical Trials Database 
• Clinical Trial Information 
• FDA Orange Book
• Drug Approval Dates
Outcomes & Analysis
• Outcomes
• Frequency of Active 
Comparator over Time
• Frequency of Active 
Comparator by Trial Phase
• Analysis 
• Linear Regression 
Outcomes 
• Between 2002 and 2020, the proportion of clinical trials for acne, 
psoriasis, and eczema with an active comparator has decreased.              
(-5.2% per year, 95% CI -1.7% to -8.6%) 
Outcomes 
• Phase II studies were most 
likely to include and active 
comparator (71%), while 
phase III studies were least 
likely (32%). 
Conclusions
• Although there is a greater need for comparative 
effectiveness data in the setting of a growing number 
of available treatments, our results highlight that the 
use of active comparator trials has decreased over time
Moving Forward (Impact): 
• It will be important for clinicians, patients, payers, and 
regulators to consider strategies to encourage use of 
important trials to guide clinical decision making. 
• Our study offers a snapshot of clinical trial design. 
• Comparative Effectiveness Data 
• Cost-Benefits Analyses 
• FDA Regulated Guidelines 
Role of Patient Reported Outcomes
Absolute Lesion Reduction vs. Quality of Life Index 
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